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Varicella is a common viral disease affecting almost the
entire birth cohort. Some cases of varicella can be serious,
with 2-6% of complications. The hospitalization rate for
varicella in Europe ranges from 1.3 to 4.5 per 100,000
population/year and up to 10.1% of hospitalized patients
report permanent or possible permanent sequelae.
In countries where routine childhood vaccination against
varicella has been implemented, it has had a positive effect
on disease prevention and control. Mathematical models
indicate that this intervention strategy may provide eco-
nomic benefits for the individual and society[1].
Despite this evidence and recommendations for varicella
vaccination by official bodies such as the World Health
Organization and scientific experts in the field, in Italy the
last National Plan for Vaccine Prevention 2012-2014 says
that vaccination against chickenpox will be included
among those active and free offer for all new born Italian
from 2015.
Actually only eight Italian Regions under-toke universal
varicella vaccination programs, in many cases with wide-
spread use of the vaccine MPRV.
The data of Tuscany[2], where the universal vaccination
began in the end of 2008 using the quadrivalent vaccine
MPRV co-administered with meningococcal C, show a
marked reduction of chickenpox in the 2009-2011 period,
compared to the prevaccination era (2005-2007). The
avoided cases are estimated approximately 42,000 and the
hospitalizations are decreased from 3.5/100,000 to 2,6/
100,000. The varicella avoided hospitalizations can be eval-
uated as 115 in three years.
The reactogenicity data regarding the quadrivalent vac-
cine measles-mumps-rubella-varicella (MPRV) are dis-
cussed because an increased relative risk of febrile seizures
after this vaccination, respect to the administration separate
and simultaneous MMR and varicella monovalent, is
reported.
The Tuscan pharmacovigilance data on MPRV in the
last three years 2009-2011, did not indicate any increase of
the risk of adverse events compared to the administration
of the separate two preparations.
For these reasons, although a note of the Ministry of
Health in 2012 invited to use vaccination separate MMR +
V in the first dose, Tuscany decided to continue to use
MPRV vaccine also in the first dose.
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